Edwards Lifesciences, TAVR

11 Analysts Have This To Say About Edwards Lifesciences
In the latest quarter, 11 analysts provided ratings for Edwards Lifesciences EW, showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
Edwards Lifesciences Is Poised For Solid Growth In 2025—Analyst Highlights TAVR Growth, Margin Expansion
Edwards Lifesciences Corporation (NYSE:EW) shares are trading higher on Thursday. Stifel analyst Rick Wise upgraded Edwards from Hold to Buy, raising the price forecast to $90 from $75. Wise suggests that recent conversations with six Transcatheter aortic valve replacement (TAVR) physicians and a follow-up survey of thirty doctors support the view that TAVR growth could re-accelerate in 2025.
Edwards Lifesciences upped to Buy at Stifel on TAVR growth
Edwards Lifesciences (NYSE:EW) traded higher on Thursday after Stifel upgraded the heart device maker to Buy from Hold, citing a turnaround in its position in the market for transcatheter aortic valve replacement (TAVR).
Stifel Upgrades Edwards Lifesciences (EW)
Fintel reports that on January 30, 2025, Stifel upgraded their outlook for Edwards Lifesciences (NYSE:EW) from Hold to Buy. Analyst Price Forecast Suggests 12.29% Upside As of January 28, 2025, the average one-year price target for Edwards Lifesciences is $79.
Edwards Lifesciences Corp. stock underperforms Friday when compared to competitors
Edwards Lifesciences Corp. closed 24.63% below its 52-week high of $96.12, which the company reached on March 28th.
Edwards Lifesciences Corporation (EW): A Bull Case Theory
We came across a bullish thesis on Edwards Lifesciences Corporation (EW) on Substack by Natan. In this article, we will ...
Edwards Lifesciences Q4 Earnings Set to Benefit From TAVR Growth
Favorable hospitalization trend, strong adoption of transcatheter heart valves and improved procedural volume are expected to have aided EW in the fourth quarter.
Edwards Lifesciences upgraded to Buy from Hold at Stifel
Stifel analyst Rick Wise upgraded Edwards Lifesciences (EW) to Buy from Hold with a price target of $90, up from $75. The firm said that TAVR, ...
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day
Shares of Edwards Lifesciences Corp. advanced 4.86% to $72.56 Tuesday, on what proved to be an all-around great trading ...
Orange County Business Journal4d
Edwards Lifesciences Veteran Katie Szyman Named Next Masimo CEO
Edwards Lifesciences Veteran Katie Szyman Named Next Masimo CEO. The Irvine-based medical device maker last week announced ...
Smart Money Is Betting Big In Edwards Lifesciences Options
Today, Benzinga's options scanner spotted 8 options trades for Edwards Lifesciences. This is not a typical pattern. The ...
Geneos Wealth Management Inc. Decreases Stake in Edwards Lifesciences Co. (NYSE:EW)
Geneos Wealth Management Inc. decreased its stake in shares of Edwards Lifesciences Co. (NYSE:EW – Free Report) by 2.3% ...
Analysts Estimate Edwards Lifesciences (EW) to Report a Decline in Earnings: What to Look Out for
Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.